Dr. Yin concluded, "We are encouraged by the second quarter sales activity and public market orders received in recent months. We believe that the ongoing execution of our revised sales strategy and seasonal flu vaccine sales that typically take place in the second half of the year will enable continued revenue growth. We look forward to updating you on the continued progress across our vaccine development pipeline."
Financial Review for the Second Quarter Ended June 30, 2011 Sales for the second quarter 2011 were $15.7 million, up 52.5% from $10.3 million for the second quarter of 2010. During the second quarter 2011, Sinovac recorded $7.7 million in pandemic influenza vaccine sales on prior year order.
Sinovac's sales breakdown by product was as follows.Three months ended June 30,2011
$ 10,263,706Gross profit for the second quarter 2011 was $10.8 million, with a gross margin of 68.8%, compared to $8.5 million and a gross margin of 82.7% for the same period of 2010. After deducting depreciation of land use rights and amortization of licenses and permits, the gross margin was 67.9% and 81.7% for the second quarter of 2011 and 2010, respectively. The gross profit margin was adversely affected by the revenue recognition in the second quarter 2011 of the prior pandemic flu vaccine order that had a lower gross margin than other vaccine products.
Selling, general and administrative expenses for the second quarter 2011 were $5.0 million, compared to $4.0 million in the same period of 2010. SG&A expenses as a percentage of second quarter 2011 sales were 31.8%, compared to 38.9% during the second quarter of the pr
|SOURCE Sinovac Biotech Ltd.|
Copyright©2010 PR Newswire.
All rights reserved